Nephrogen Raises $4M Seed to Advance AI-Driven Gene Therapy Delivery for Kidney Disease

Why It Matters

A successful delivery platform could deliver curative gene‑therapy for PKD and other hereditary kidney disorders, reducing the need for dialysis and transplants for millions of patients, while demonstrating AI’s potential to accelerate biotech innovation.

Deal Summary

Nephrogen, a biotech startup combining AI and gene‑editing delivery tech to target kidney disease, is raising a $4 million seed round to advance its delivery mechanism and drug into clinical studies anticipated in 2027.